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Abstract: The authors reviewed contribution of Kumamoto University group to the
progress of the studies on transthyretin (TTR)-related familial amyloidotic polyneuropathy (TTR-
related FAP) for 42 years (from 1967 to 2009). Andrade (1952) ﬁrst described a large group of
patients with FAP in Portugal and Araki et al. (1967) in second discovered similar FAP patients in
Arao, Kumamoto, Japan. Owing to progress in biochemical and molecular genetic analyses, FAP is
now believed to occur worldwide. As of today, reports of about 100 diﬀerent points of single or two
mutations, or a deletion in the transthyretin (TTR) gene, have been published. The authors’ group
has made pioneer works for study of FAP in the world. The focus on therapy in amylodosis will
increase sharply as an impetus in near future, and successful treatments are expected.
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Introduction
Familial amyloidotic polyneuropathy (FAP) is a
hereditary amyloidosis in which amyloidogenic mu-
tated transthyretin (ATTR), apolipoprotein A-I
(AApoA-I), and gelsolin (Agel) have been identiﬁed
as FAP-related amyloidogenic proteins.1) Of these
proteins, ATTR is the most common throughout the
world.2)–4) Andrade ﬁrst reported a large group of
patients with FAP ATTR Val30Met in Portugal in
1952,5) and other large foci have been discovered in
Japan by Araki et al.6) and in Sweden by Andersson
et al.7) Until 20 years ago, FAP was thought to be
a disease restricted to endemic occurrence in those
areas. However, owing to progress in biochemical and
molecular genetic analyses, this disease is now
believed to occur worldwide (Fig. 1).2)–4)
As of today, reports of about 100 diﬀerent
points of single or double mutations, or a deletion
in the TTR gene, have appeared8); the majority of
cases involve small kindred or no family history.
Of TTR-related FAP types, FAP ATTR Val30Met
is the most common, and only FAP ATTR
Val30Met is found in large foci of patients,
although the reason for this characteristic remains
to be elucidated. Recently, several phenotypes of
FAP, including the polyneuropathic, oculoleptome-
ningeal, and cardiac types, have been reported,9)–12)
and heterogeneity of clinical symptoms is recog-
nized even for the same mutation of the TTR
gene.
In Japan, Araki et al. ﬁrst reported a focus of
patients with FAP ATTR Val30Met in Arao
district, Kumamoto,6) and Kito reported another
focus in Nagano in Honshu Island.13) More than 25
points of mutation in the TTR gene have now been
reported from the long islands of Japan, from the
south to the north (Fig. 2).8),14) In this review, we
present the history of our FAP research progress by
Kumamoto group, and current clinicopathological,
biochemical, molecular genetic, and epidemiological
aspects of TTR-related FAP. In addition, we
introduce a simple new diagnostic procedure for
TTR-related FAP.
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of the disease in Japan
The discovery of a new disease in the history of
medicine is often regarded as a chance occurrence.
FAP was not documented in Japan until 1966, when
Araki examined a patient who had been referred by a
physician at the Arao City hospital in Kumamoto,
Japan.
The patient was suﬀering from a sensory
disturbance of the lower extremities, diarrhea, and
impotence. At ﬁrst, a physician at the Arao City
Hospital suspected this patient might have been
suﬀering from subacute myelo-optico-neuropathy
(SMON). SMON is a disease of Clioquinol intoxica-
tion characterized by sensory disturbance in the
lower limbs, pyramidal signs, and occasional visual
disturbance preceded by abdominal symptoms. 5-
chloro-7-iodo-8-quinolinol (Clioquinol) had been
widely used in Japan to treat dysentery and
diarrhea. A nationwide survey in 1972 revealed a
cumulative total of 11,007 patients with SMON;
618 patients died between July 1967 and December
1981.
Araki found amyloid deposition in the biopsy
specimen of the sural nerve taken from the referred
patient, and the diagnosis of SMON in this patient
could not be substantiated. Family members related
to this patient showed similar clinical features. The
representative case is as follows.
Fig. 1. Distribution of FAP in the world. Locations of foci of FAP ATTR Val30Met patients described in previous reports and obtained
from personal communications are presented.
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Fig. 2. Distribution of FAP in Japan. Localization of various types of FAP patients in previous reports are presented in this ﬁgure.
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1) History The ﬁrst patient, a 46-years-old
farmer became impotent at age of 40.
Two years later, he began to have a tingling
sensation and numbness in the toes, ascending to the
levels of both ankles 1 year later.
At age 44, he had constipation and diarrhea
alternately. In the meantime, paresthesia and an-
algesia slowly ascended to the upper thighs and he
became incontinent of urine. He became diﬃcult to
raise his legs in walking and he stumbled often.
About this time, he sometimes experienced dizziness
when he suddenly stood up and this episode became
frequent. At age 45, he noticed numbness in the
hands and diarrhea worsened, with occasional incon-
tinence.
On May 26, 1966, at age 46, he was admitted to
Neurological Institute, Kyushu University.
2) Examinations He was malnourished. The
skin of all four extremities was dry and cool. The
blood pressure was 115/85mmHg in the supine
position, but 58/10mmHg in the sitting position.
Orthostastic hypotension was marked. Hoarseness
was noticed, but other cranial nerves were unremark-
able. Muscular atrophy and weakness were detected
in all extremities; especially severely in the distal
portions of the lower extremities. Deep tendon
reﬂexes were slightly decreased in the upper extrem-
ities and absent in the lower. Superﬁcial sensations
were decreased in all four extremities, more severely
in the periphery, but deep sensations were relatively
preserved. Sural nerve biopsy showed amyloid
deposition. Muscular atrophy and sensory impair-
ment progressed thereafter. The patient’s high fever
continued for 2 months prior to November 13, 1967
when he died of urinary tract infection after 6 years
from the onset of impotence.
3) Abnormal laboratory data during the
hospitalization Red blood count was 322 × 104,
Electrocardiogram showed 1st degree A-V block, and
cerebrospinal ﬂuid obtained by lumbar puncture
showed clear, colorless, cell counts 3 (all lympho-
cytes), and total protein 112mg/dl. Motor nerve
conduction velocities decreased in four limbs. electro-
myogram showed giant and complex motor unit
potential in the limb muscles.
4) Autopsy ﬁndings An autopsy for an FAP
patient revealed that prominent amyloid deposition
was detected in the peripheral and autonomic
nervous systems. The brain and spinal cord were
unaﬀected. Amyloid deposition in the general organs
was found chieﬂy in the kidneys, spleen, and around
the walls of small blood vessels.
3. Reports on FAP
In 1967–1968, Araki et al. ﬁrst reported a large
focus of FAP in the area of Arao, Kumamoto,
Japan.6) The clinical and pathological ﬁndings were
similar in both Portuguese and Japanese patients.
Since then, there have been several reports of families
in Ogawa village region in Nagano prefecture by Kito
in 1973 and in other parts of Japan with similar
ﬁndings. FAP was also reported in Sweden, UK,
Germany, Greek, Poland, USA, and others.
4. Identiﬁcation of amyloid precursor protein
In 1978, Costa et al. reported in FAP of
Portuguese origin that the FAP amyloid ﬁbrils are
closely related to the 13,745 dalton protein.15) In
1983, Pras et al. reported in Jewish origin that the
amyloid protein contains 127 amino acid residues,
and was identical to a human prealbumin subunit.
In Japan, Tawara et al. (1983) have described the
structural identiﬁcation of an amyloid ﬁbril protein
of 14K dalton in Japanese patients and have
elucidated that the amyloid precursor protein is a
variant TTR with a single amino acid substitution of
varine by methionine at the 30th portion of the
amino acid sequence of wild type TTR.16) This was
the ﬁrst discovery of molecular analysis in FAP.
5. TTR related FAP syndromes
Our study group has found three major FAP
foci in Kumamoto, Nagasaki, and Fukuoka prefec-
tures in Kyushu, Japan. They show diﬀerent clinical
features.
(1) FAP ATTR Val30Met One hundred
eighty-six patients with FAP ATTR Val30Met
were registered from 1967 to 2008 in Arao district,
Kumamoto, Japan. The inheritance pattern is
autosomal dominant with a high penetrance rate
and an equal sex ratio. The symptoms are ﬁrst
recognized when the patient is between 18 and 83
years of age, with a mean age at onset of 35.4 years.
The age at onset in this type was found to show
anticipation, as seen in FAP patients in other
endemic areas.2),9)
The disease is slowly progressive and reaches the
terminal stage in 10.8 years (Fig. 3). Evidence of a
sensorimotor peripheral neuropathy is usually found
in the lower limbs. Dissociation of sensory impair-
ment is common, with pain and temperature
sensation being the most severely aﬀected. Autonom-
S. ARAKI and Y. ANDO [Vol. 86, 696ic nervous system involvement, such as dyshidorosis,
sexual impotence, disturbances of gastrointestinal
motility (diarrhea alternating with constipation,
orthostatic hypotension, and urinary disturbances)
are frequent (Fig. 4). Cardiac and renal dysfunction
is commonly recognized during the course of the
illness. Anemia is also observed.17) Ocular involve-
ment, such as vitreous opacity, kerato-conjunctivitis,
glaucoma, and papillary disturbances, are seen.18) In
addition, to the most common FAP types, various
heterogeneous phenotypes have been observed. Clin-
ical stages of FAP are classiﬁed into 4 types with
ADL and sensory signs.19)
(2) FAP ATTR Tyr114Cys This type of FAP
was discovered in Shimabara district, Nagasaki,
Japan.20) The symptoms were ﬁrst recognized when
stage 1 stage 2 stage 3 stage 4
Fig. 3. FAP patients in each clinical stage. Typical features of FAP patients in each clinical stage as described in ref. 12 are
demonstrated in the pictures.
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Fig. 4. Clinical manifestations in patients with FAP ATTR Val30Met. One hundred sixty-nine patients with FAP ATTR Val30Met
were registered from 1968 to 2003 in Arao district, Kumamoto, Japan.
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with a mean age at onset of 38.9 years. So far, 35
patients have been conﬁrmed as having FAP ATTR
Tyr114Cys. All patients showed decreased visual
acuity as initial symptoms. Vitreous opacityes,
cardiac failure, and autonomic dysfunction are the
main symptoms recognized during the course of
the illness. Sensory-dominant polyneuropathy is
mild and less common compared with FAP ATTR
Val30Met.20) A patient of this genotype was also
found in Busan, Korea. Laboratory examinations
have revealed extremely low serum TTR levels;21) a
conformentional change in ATTR Tyr114Cys may
facilitate aggregation of the TTR.
Attention has recently focused on the ocular-
leptomeningeal form of FAP (induced by several
point mutations in the TTR gene), as well as on the
advanced stages of ATTR Val30Met-type FAP.18)
Cerebral amyloid angiopathy and ocular amyloidosis
are common characteristic clinical features in those
types of FAP. Cerebral amyloid angiopathy is
characterized by amyloid deposition in the media
and adventitia of medium and small arteries, arterio-
les, and occasionally veins of the cortex and
leptomeninges. Typical nervous system manifestation
included cerebral infarction, hemorrhage, hydroce-
phalus, ataxia, spastic paralysis, convulsion, and
dementia. These symptoms are often found in several
types of TTR-related FAP and lead to classiﬁcation
into oclulomeningeal amyloidosis, in which amyloid
deposition is also found in vitreous bodies and other
tissues of the eye.22)–24)
As the same way as other type of leptomeningeal
form of FAP, amyloid deposition was found in the
leptomeninges and in perivascular areas of the
cerebral vessels and loss of consciousness, transient
ischemic attacks, and cerebral bleeding were ob-
served in FAP ATTR Tyr114Cys. The duration of
the disease is shorter than that of other types of TTR
related FAPs.20)
(3) FAP ATTR Ser50Ile This type was
discovered in Kasuya district, Fukuoka Prefecture in
1972. In addition, we found 13 new cases, and so
totally 29 patients in the district. Cardiac failure is
a primary clinical manifestation25) (Sakashita et al.
2000) and is a commonly recognized as the ﬁrst
symptom. Sensory-dominant polyneuropathy and
autonomic failure are less common than in FAP
ATTR Tyr114Cys.
(4) Other novel mutations in the TTR gene
Including the above-mentioned 3 mutations, a total
of 235 FAP patients with three diﬀerent mutations
have been recognized. They are Glu42Gly,26)
Val30Leu,27) Tyr114His,28) Ser49Ile,29) and com-
pound heterozygote Arg104His/Val30Met.21) Ando
et al. (2000) reported on the ﬁrst Japanese FAP
ATTR Val30Met identical twins.30) ATTR Asn124S-
er with colocalization of 5 light chain was identiﬁed
in Italian sample by Bergström et al. who studied in
Kumamoto 2007.31)
6. Pathology
A clinicopathological, histo-chemical, immuno-
histohemical, and ultrastructural study of materials
obtained by autopsy or biopsy in 17 patients were
performed by Takahashi et al. (1991).32) In the
autopsy cases, amyloid deposits were predominant
in the peripheral nerve tissues, autonomic nervous
system, choroid plexus, cardiovascular system, and
kidneys. Amyloid involvement in the anterior and
posterior roots of the spinal cord, spinal ganglia,
thyroid, and gastrointestinal tract was also frequent.
In the cardiac conduction system, amyloid deposi-
tions were prominent in the sino-atrial node and in
the limbs of the intraventricular bundle. In sural
nerve biopsy specimens from patients with early-
stage FAP, amyloid depositions were observed in the
small vessel walls and the surrounding tissues. In the
advanced cases, amyloid deposits were found in the
subperineural and/or epineural regions. The numbers
of myelinated and unmyelinated nerve decreased
markedly, which indicated degenerative changes in
Schwann cells. Degenerative changes in the axon,
myelin sheath, and Schwann cells and the decrease in
collagen ﬁbers paralleled the severity of the periph-
eral nerve disturbances.
Morphometric data on the number and caliber of
myelinated ﬁbers in the sural nerve biopsy specimen
from patients with early-stage FAP showed a greater
reduction of small-caliber ﬁbers than of large-caliber
ﬁbers. In patients with more advanced FAP, the
numbers of myelinated ﬁbers were decreased.33)
Araki et al. (2000) summarized pathological ﬁndings
on FAP ATTR Val30Met.34)
7. Biochemical aspects of amyloidogenesis
The amyloid formation working hypothesis
established by substantial studies, gave rise to the
idea that stabilizing tetrameric TTR is promising
method for prevention of amyloid formation.
McCutchen et al. ﬁrst demonstrated this concept
by using recombinant wild-type TTR and variant
TTR. Normal TTR behaves as a tetramer and binds
to retinol binding protein (RBP) and thyroxine (T4)
S. ARAKI and Y. ANDO [Vol. 86, 698in plasma.35) Tetrameric TTR is not itself amyloido-
genic, but dissociation of the tetramer into a compact
non-native monomer with low conformational stabil-
ity can lead to amyloid ﬁbril formation.36) Although
several of TTR single-site mutations have a normal
tetrameric structure under physiological condition,
these mutations signiﬁcantly destabilize the tet-
ramer. Recent biochemical and pathological studies
further revealed that instability of the tetrameric
form of TTR by mutation, especially FAP ATTR
Val30Met, leads to amyloid formation in the tissues
of FAP patients.35) It’s interesting to note that
subjects possessing the TTR Thr119Met gene are
asymptomatic carriers, and that compound hetero-
zygotes having ATTR Val30Met and TTR
Thr119Met genes show very mild FAP symptoms of
have no symptoms.37) Alves et al. demonstrated by
semidenaturing isoelectric focusing that patients
possessing TTR Thr119Met or ATTR Val30Met/
TTR Thr119Met genes showed marked TTR tetra-
meric structural stability.38),39) Terazaki et al. also
reported an interesting late-onset compound hetero-
zygote patient with FAP ATTR Val30Met/TTR
Arg104His who had very mild and slowly progressive
clinical symptoms and whose tetrameric TTR stabil-
ity was greater than that of the TTR from healthy
volunteers.21),38) These evidences suggest that stabi-
lizing the tetrameric TTR, as a potential therapeutic
strategy, is a prerequisite for prevention of amyloid
formation.40) On the basis of this concept, several
treatments were proposed and examined.
(1) Various nonsteroidal anti-inﬂammatory
drugs (NSAIDs) derivertives Because thyroxine
(T4) is one of the most important molecules for
stabilizing TTR in tetrameric form, T4-based ther-
apeutic drugs have been proposed. Binding of T4 and
their derivatives stabilizes the native conformation of
TTR and inhibits amyloid formation in vitro and
possibly in vivo. In fact, it has been proposed that,
in the cerebral spinal ﬂuid (CSF) where a high
concentration of TTR with bound T4 is found, the
protein is in the stable tetrameric conformation and
does not lead to detectable TTR amyloid formation
in the brain.41)
Baures et al. reported that various NSAIDs have
potential for stabilizing the tetrameric TTR. Several
NSAIDs, which bind and inhibit the cyclooxygenases,
also bind to TTR as mimic compounds of T4.41) The
structure of NSAIDs resembles the structure of T4
and these drugs bind to TTR via a T4 binding site.
Peterson et al. demonstrated that the three-dimen-
sional structure of TTR with ﬂufenamic acid (FLU),
a derivative of NSAIDs that is a more eﬃcacious
TTR amyloid inhibitor than the natural ligand T4.
Difulnisal and ﬂufenamic acid exhibit notable inhib-
ition of both acid-mediated aggregation and urea-
mediated tetramer dissociation of the most common
disease associated variants. Tojo et al. reported that
therapeutic serum concentrations of difulnisal (100–
200µM) stabilized serum variant TTR tetramer more
eﬀective than those of ﬂuenamic acid (35–70µM).
Sekijima et al. also demonstrated that oral admin-
istration of diﬂunisal mediates kinetic stabilization of
TTR in human serum.42) Furthermore, structurally
related derivatives of NSAIDs were also exploited to
enhance the selectivity and reduce the adverse eﬀect.
Various reports conﬁrmed these ﬁndings and this
concept is now widely accepted.43)
(2) Cr3+ Recent studies suggested that certain
metal ions aﬀect amyloidogenesis in several types of
amyloidosis. In FAP, metal ions may inﬂuence the
stability of the tetrameric form of TTR. Sato et al.
therefore investigated whether various metal ions
(e.g.,Z n 2+,C u 2+,C a 2+,F e 3+,A l 3+,C r 3+)a ﬀect
amyloidogenesis of wild-type TTR and ATTR.
Among the metal ions, Cr3+ increased the tetrameric
stability of both wild-type and ATTR Val30Met, and
suppressed TTR amyloidogenesis. It is unlikely that
Cr3+ binds to T4-binding sites of TTR, because of its
chemical structure. Cr3+ may increase the thermody-
namic stability of TTR tetramer by facilitating the
binding of T4. Because Cr3+ is a component of health
foods that is widely used throughout the world,
administration of this metal ion was thought to be a
good candidate for therapy. However, at the serum
concentration, Cr3+ had no signiﬁcant eﬀect on TTR
stability in serum. While serum Cr3+ concentration
will increase after Cr3+ supplementation, it is still
very low compared to the concentration of TTR,
likely explaining why stabilization is not observed.
However, Cr3+ could be useful for treating TTR
amyloidosis by enhancing the eﬀects of diﬂunisal,
because the eﬀects of T4 and Cr3+ are not competitive
but cooperative.44) Although no obvious eﬀect of
Cr3+ on patients was seen, further in vivo evaluation
of the eﬀects is needed.
(3) Fx-1006A Tremendous eﬀorts revealed the
possibility of stabilization of the tetrameric form of
TTR as a potential therapeutic strategy. Ongoing
biochemical and pathological studies explored further
potentiality of this therapy. It’s noteworthy that Fx-
1006A, a potent and selective stabilizer for tetrameric
TTR, is underway in a multinational Phase II/III
clinical study in patients with FAP worldwide.
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molecules that bind to the TTR increasing the
protein stability and thereafter inhibiting amyloid
ﬁbrillogenesis have been tested. In fact, several small
molecules, such as plant-derived ﬂavones and xan-
thones, the synthetic estrogen diethylstilbestrol, 2,4-
dinitrophenol (DNP) as well as 3,5-diiodosalicylic
acid were shown to have high aﬃnity towards TTR
and to inhibit amyloid formation in vitro.45)
8. Molecular genetics
The human TTR gene was localized at 18p 11.1-
q 12.3 and structure was ﬁrst determined by Tsuzuki
et al. (1985).46) Mita et al. (1984) cloned cDNAcord-
ing for human TTR from cDNA library prepared
from human liver.47) A diagnosis of FAP ATTR Val
30 Met can be made by restriction endonuclease Nsi1
with Southern blotting procedures.48) In 100 abnor-
mal TTR genes, 0, 36, 40, and 24 points of mutation
were detected in exons 1, 2, 3, and 4, respectively; a
deletion in the TTR gene also occurred. The main
sites of production of TTR conﬁrmed by in situ
hybridization methods are the liver, retinal pigment
epithelium, choroid plexus of the brain, ,-cells in the
pancreatic islets and visceral york sac endoderm.49),50)
9. Animal models
Shimada and Yamamura et al. (1989)51) devel-
oped transgenic mice carrying and expressing the
human mutant TTR ATTR Val30Met. Yi et al.
(1991)52) analyzed amyloid deposition in the mice
and found that deposition started in the gastro-
intestinal tract, cardiovascular system, and kidneys
6 months after birth and extended to various other
organs and tissues with advancing age. The pattern
of amyloid deposition in the mouse at age 24 months
was similar to that observed in human autopsy cases
of FAP, except for the absence of amyloid in the
choroid plexus and the peripheral and autonomic
nervous systems. Amyloid deposited was shown to be
composed of human TTR and, in addition, mouse
serum amyloid P-component. These results clearly
indicate that human variant TTR produced in
transgenic mice is deposited as a major component
of amyloid ﬁbrils in various organs and tissues. Thus,
this animal model is useful for analyzing how amyloid
deposition is initiated and proceeds in FAP.
Murakami et al. (1992)53) induced chronic
inﬂammation in the transgenic mice, but secondary
amyloidosis was observed, and there were no changes
in quantitative amyloid deposition compared with
the mice without inﬂammation.
Our group newly developed the transgenic rat
having human ATTR Val30Met gene which express
the human variant gene in the liver, retina, and
choloid plexus in collaboration with Jichi Medical
University research group.54) The transgenic rat is
useful for the experiments of liver transplantation,
and examining the eﬀect of therapeutic drugs.
10. Clinical genetic testing
For the screening of FAP patients, we ﬁrst
perform mass spectrometric analysis, with a system
for serum and cerebrospinal ﬂuid that uses meth-
ods such as electron spray ionization-mass spec-
trometry (ESI-MS)55) and matrix-assisted laser de-
sorption ionization/time-of-ﬂight mass spectrometry
(MALDI/TOF-MS).56) With this system, the pres-
ence or absence of mutations in the TTR gene can be
determined. A shift in the molecular mass caused by
substitution of amino acids can be detected as a peak
that diﬀers from those identifying the wild-type TTR.
Recently, to shorten the time to screen the FAP
suspected serum samples, we newly applied protein
chip system using surface-enhanced laser desorption/
ionization (SELDI/TOF MS). We can detect variant
TTRs within 3 hours in a several µl serum samples.57)
Another method, in addition to polymerase
chain reaction and restriction endonuclease analysis,
has recently been used for screening patients who
have a family history or typical clinical manifesta-
tions, or who come from an endemic FAP area. By
means of the LightCycler method, we can detect the
presence or absence of a TTR mutation in 1 hour.
(1) Detection of ATTR Val30Met via Light-
Cycler LightCycler technology can detect muta-
tions quickly and accurately by using ﬂuorescent
hybridization probes and melting curves. For exam-
ple, an anchor probe (5′-TGTGGCCGTGCATGTG-
T-3′-FITC, in which the underlined nucleotide is the
normal nucleotide) and a sensor probe (LC Red 640-
5′-CAGAAAGGCTGCTG ATGACACCTGGGAG-
CCATTTGCCTCTGGG-3′-OH) were used to detect
ATTR Val30Met. Because a single mismatch can
signiﬁcantly reduce the melting temperature of the
oligonucleotide, the melting temperature is reduced
when the ampliﬁed gene encodes ATTR Val30Met.
Therefore, it is possible to discriminate among a
normal subject, an FAP ATTR Val30Met homo-
zygote, and an FAP ATTR Val30Met heterozygote
by using melting curve analysis.8)
(2) Nonisotopic single-strand conformational
polymorphism Single-strand conformational poly-
morphism (SSCP) was applied with samples with
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which a mutation was present. However, a conven-
tional type of SSCP requires a radioisotope to
perform the procedure. Therefore, to avoid the need
for a radioisotope, we recently developed SSCP
analysis with capillary electrophoresis (SSCP-CE)
in which a forward primer labeled with Cy5 and a
microchip (iChip 12; Hitachi Chemical Co., Ltd.,
Tokyo, Japan) ﬁlled with i-S gel 3 (Hitachi Chemical
Co., Ltd.) are used. An example of SSCP-CE analysis
of an FAP ATTR Tyr114Cys heterozygote is
presented herein. As shown in Fig. 3B, an additional
peak is observed when the ampliﬁed gene encodes for
ATTR Tyr114Cys.8)
With the combined diagnostic methods, such as
pathologic, mass spectrometric, and molecular genet-
ic examinations, screening of FAP patients become
simpler and more accurate. Since those methods can
not always reveal all mutations in TTR gene of FAP
patients, we determine the presence or absence of a
mutation with an auto-sequencer.
(3) Other diagnostic methods Ando et al.
presented a histochemical method of diagnosis of
ATTR Val30Met by using FAP patients’ hair and
monoclonal antibody supplied by Costa et al.58) Also,
Ando et al. demonstrated abundant abnormal ocular
vessels in patients with FAP ATTR Val30Met, which
has diagnostic value.59)
11. Epidemiology
The presence of patients with TTR-related FAP
has been conﬁrmed in more than 30 countries, with
FAP ATTR Val30Met patients veriﬁed in more than
15 countries. Only FAP ATTR Val30Met has large
foci in the world, although the reason for this is not
known. Holmgren et al. performed an epidemiological
study in the northern part of Sweden and estimated
that the number of ATTR Val30Met gene carriers
in a total population of 500,000 in the area was
approximately 7,500, although the penetrance of the
mutation was as low as about 2%.60) To elucidate the
reason for this phenomenon, we examined the
haplotype studies in the worldwide. The analyses
revealed that Swedish FAP patients had diﬀerent
haplotypes compared with those of Japanese and
Portuguese. By 2007, more than 3,000 FAP ATTR
Val30Met patients from 489 pedigrees had been
diagnosed at Centro de Estudos de Paramidoidose in
Porto, Portugal. So far, more than 3,000 FAP
patients have been registered in Portugal (personal
communication). In Japan, more than 400 FAP
patients were found in two endemic foci: one is Arao
city in Kumamoto prefecture, and the other is Ogawa
village in Nagano prefecture. In addition, 44 FAP
kindred with Val30Met TTR were traced. They were
genealogically independent and were geographically
scattered throughout Japan. Recently, the third
largest focus of this disease was identiﬁed in Noto
peninsular, Ishikawa prefecture.
12. Origin of FAP ATTR Val30Met
As described above, in the 1960s, large foci of
patients were found in Japan and Sweden in addition
to Portugal. These three countries are geographically
distant, and a consanguineous relationship between
foci has not been identiﬁed. The issue of whether
there is a common origin in the foci for a mutant
allele has not been resolved. Furthermore, Continho
hypothesized that a mutant allele in the Portuguese
kindred could be one origin of the mutation for FAP
foci throughout the world, including Japan, Europe,
North and South America, and Africa.61) This
hypothesis was based only on well-known historical
relations and thus far it has not been scientiﬁcally
tested. Ohmori et al. compared haplotypes in several
foci of FAP patients and discovered that a common
founder could be conceivable for Japanese and
Portuguese patients, and for Portuguese and Spanish
patients, but not for Swedish and other patients.
Additional studies of genotypes and phenotypes are
needed.
13. Liver transplantation
Liver transplantation has been reported to halt
the progression. According to data in the Familial
Amyloidotic Polyneuropathy World Transplant
Registry (FAPWTR), More than 60 centers in 17
countries have performed orthotopic liver trans-
plantation (OLT) for FAP. By the end of 2008, more
than 1,500 patients have undergone OLTs. Survival
of the patients has been excellent (overall 5-year
survival of 80%) and comparable to the survival for
OLT performed for other chronic liver disorders, but
a longer follow-up is needed to compare the outcome
after OLT with the natural course of the disease. The
main cause of death was related to cardiac diﬃculties
(40%).62)–68)
In our group, we had 42 FAP patients (ATTR
Val30Met patients: 38, Ser50Ile: 1, Tyr114Cys: 3,
and Ser33leu: 1) who underwent liver transplantation
from 1994 to 2009. More than 90% of the trans-
planted patients have a full time work, and fortu-
nately 5-year-survival rate is 100%. From 1994 to
1998, liver transplantation was performed using a
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transplantation using a living donor was performed:
simultaneously 22 patients with severe liver diseases
underwent domino liver transplantation using a
resected FAP patient’s liver.
The use of sequential liver transplantation
with dissected livers from FAP patients started in
Portugal; more than 500 patients have received FAP
patients’ livers. Several second recipients trans-
planted FAP patient’s liver started to show FAP
symptoms in several years after liver transplanta-
tion.69),70) We must carefully follow up such trans-
planted patients.
14. New therapeutic approaches for FAP
Although liver transplantation is the only
therapy to halt the clinical manifestations of trans-
thyretin (TTR) related FAP, the therapy has given
rise to have several problems. An alternative treat-
ment is needed. After the precursor protein of
amyloid ﬁbrils in FAP was determined in 1983,
several diﬀerent therapeutic approaches have been
investigated as an essential therapy for FAP: (1)
reduction of variant TTR levels in plasma, (2) down-
regulation of TTR gene of mRNA (3) inhibition of
amyloid deposition, (4) stabilization of the tetrameric
TTR structure and (5) replacement of the variant
TTR gene with the normal TTR gene (which can be
achieved by liver transplantation or by gene therapy)
(Fig. 5). In our research group, as gene therapy for
variant TTR gene, gene conversion therapy using
wild type TTR single stranded oligonucleotides, or
gene silencing using siRNA for variant TTR gene has
been studied. In addition, eﬀect of antibody therapy
for targeting misﬁled variant TTR has been exam-
ined in vivo. Both projects are now on going, and
getting better results in vivo. In near future, these
therapeutic projects may be in phase study.
Prevention of amyloid formation
BSB
Antibody therapy
Radical scavenger
Down-regulation of TTR gene mRNA
Injection of a large amount of normal TTR
Replacement of the variant TTR gene with the normal TTR gene
Liver transplantation
Gene therapy
Stabilization of the tetramericTTR structure
NSAIDs
Cr3+
Fx-1006A
Dissolution of amyloid fibrils
IDOX
Tetracycline
Amyloid
Fibrils
Monomeric TTR
TTR deposits
Tetrameric TTR
Reduction of variant TTR levels
Plasma exchange
Affinity column chromatography
TTR absorption column chromatography
Laser photo coagulation
Liver Liver
Dissociation
Misfolding
Polymerization
Fig. 5. Working hypothesis for TTR amyloid formation and therapies. On the basis of amyloid formation mechanism, several promising
therapies are considering.
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TTR-related amyloidosis is not an insigniﬁcant
disease, and many more aﬀected patients would likely
be found if more careful and precise investigations
were performed. The collaboration of neurologists,
gastroenterologists, ophthalmologists, and cardiolo-
gists is needed to make a deﬁnitive diagnosis.
Although liver transplantation can holt the progres-
sion of FAP, it has several serious problems. New
therapeutic approaches, such as gene therapy, and
antibody therapy should try to be examined.
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